

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to the accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



NOTICE OF EXTRAORDINARY GENERAL MEETING

PRECAUTIONARY MEASURES FOR THE EPIDEMIC AT THE EGM

The following precautionary measures will be implemented by the Company at the EGM to prevent the spreading of the COVID-19:

- (1) Compulsory body temperature checks
- (2) Submission of health declaration form
- (3) Wearing of surgical face mask
- (4) No refreshments will be provided and no corporate gifts will be distributed

Attendees who do not comply with the precautionary measures (1) to (3) above may be denied entry to the EGM venue, at the absolute discretion of the Company, as permitted by law.

The Company encourages Shareholders to consider appointing the chairman of the EGM as their proxy to vote on the relevant resolutions at the EGM as an alternative to attending the EGM in person.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of China NT Pharma Group Company Limited (the “**Company**”) will be held at No. 1 HuaLing Road, SuZhou Industrial Park, SuZhou, the PRC on Tuesday, 13 September 2022 at 10:00 a.m. for the purpose of considering and, if thought fit, passing with or without amendments, the following resolution of the Company:

ORDINARY RESOLUTIONS

“**THAT:**

- (a) the following transaction documents (the “**Transaction Documents**”):
 - (i) the licensing and collaboration agreement dated 21 June 2022 entered into between Green-Life Technology (Hong Kong) Company Limited, a wholly-owned subsidiary of the Company, as licensee (the “**Licensee**”) and Abcentra LLC as licensor (the “**Licensor**”) (a copy of which has been produced to the EGM and

marked “A” and initialled by the chairman of the EGM for the purpose of identification) in relation to commercialization of a monoclonal antibody (i.e. Orticumab) (the “**Technology**”) developed by the Licensor for the treatment of atherosclerotic cardiovascular diseases, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and calcified aortic valve diseases;

- (ii) the licensing agreement to be entered into between the Licensee and the Licensor (a copy of which has been produced to the EGM and marked “B” and initialled by the chairman of the EGM for the purpose of identification) in relation to the grant of the exclusive and perpetual license of the exclusive and perpetual rights to commercialise the Technology in the People’s Republic of China (“**PRC**”), Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand;
- (iii) the consultancy agreement to be entered into among the Company, the Licensee and Mr. Wang Minzhi (a copy of which has been produced to the EGM and marked “C” and initialled by the chairman of the EGM for the purpose of identification) in relation to the provision of consultancy services on research and development of the Technology and registration of the product(s) to be developed from the Technology with the relevant regulatory authorities in the PRC to the Company; and
- (iv) the consultancy agreement to be entered into among the Company, the Licensee and Dr. Gao Gui (together with Mr. Wang Minzhi, as “**Consultants**”) (a copy of which has been produced to the EGM and marked “D” and initialled by the chairman of the EGM for the purpose of identification) in relation to the provision of consultancy services on research and development of the Technology and registration of the product(s) to be developed from the Technology with the relevant regulatory authorities in the PRC to the Company (the Transaction Documents referred to in (iii) and (iv) collectively as “**Consultancy Agreements**”);

and the transactions contemplated thereunder be and are hereby approved, ratified and confirmed; and

- (b) subject to the fulfilment of the conditions precedent of the issuance of Consideration Shares (as defined below), the directors of the Company (each a “**Director**”) be and are hereby granted a specific mandate to allot and issue 473,186,591 new ordinary shares in the share capital of the Company (each a “**Consideration Share**”) at the issue price of HK\$0.20 per Consideration Share to the Consultants as consideration for the consultancy services pursuant to the terms and conditions of the Consultancy Agreements;

- (c) any one or more Director(s) be and is/are hereby authorised for and on behalf of the Company to execute all such documents (including under seal, where applicable), to do all other acts and things deemed by him/them to be incidental to, ancillary to or in connection with the matter contemplated in and completion of the Transaction Documents, and take such action as may in the opinion of the Director(s) be necessary, desirable or expedient to implement and give effect to or in connection with the Transaction Documents and any other transactions contemplated under Transaction Documents, and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents or any terms thereof) as is/are, in the opinion of such Director(s) or the duly authorised committee of the board of Directors, in the interest of the Company and its shareholders as a whole.”

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 23 August 2022

Notes:

1. Any member entitled to attend and vote at the EGM is entitled to appoint another person as his/her proxy to attend and vote instead of him/her. A proxy need not be a member of the Company.
2. The instrument appointing a proxy and the power of attorney or other authority (if any) under which it is signed or a certified copy of such power of attorney or authority shall be delivered to the Company's share registrar in Hong Kong, Tricor Investor Services Limited, at 17th Floor, Far East Finance Centre, No. 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for holding the EGM at which the person named in the instrument proposes to vote or any adjourned thereof (as the case may be).
3. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the EGM or any adjournment thereof, should he/she so wish, and in such event, the form of proxy shall be deemed to be revoked.
4. The transfer books and register of members will be closed from Wednesday, 7 September 2022 to Tuesday, 13 September 2022, both days inclusive, for the purpose of ascertaining shareholder's entitlement to attend and vote at the above meeting, during which period no share transfers can be registered. All transfers accompanied by the relevant share certificates must be lodged with the Company's Hong Kong share registrar, Tricor Investor Services Limited, at 17th Floor, Far East Finance Centre, No. 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Tuesday, 6 September 2022.
5. The translation into Chinese language of this notice is for reference only. In case of any inconsistency, the English version shall prevail.

As at the date of this notice, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.